AK146D1
AK146D1 is Akeso's Nectin-4 × TROP2 bispecific ADC, combining the two most validated ADC addresses in one molecule.
Entered clinic in 2025 alongside Avenzo's AVZO-103 in the same target pair. Rationale: complementary expression across urothelial, breast, and lung cancers; potentially higher internalisation. Very early.
AK146D1 carries a camptothecin-derived TOP1 inhibitor; exatecan shown as the class representative.
1.Antibody binds Nectin-4 and TROP2 (bispecific) on the tumour cell surface
- Route
- IV infusion
- Schedule
- Phase 1 dose escalation
Source: clinicaltrials.gov. Doses are for orientation; the current label governs.
- Mar 2025Filing / dealChina
IND cleared; first-in-human phase 1 started source
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| China | Investigational | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"AK146D1" OR ABSTRACT:"AK146D1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AK146D1, not a curated reading list.